Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Oncolytic viruses are engineered to selectively infect and kill cancer cells, sparing healthy tissues.
• However, oncolytic viruses have been observed to infect non-tumor cells, a phenomenon whose implications for cancer therapy remain unclear.

Purpose of the Study:

• To review the infection of non-cancerous targets by oncolytic viruses.
• To investigate the mechanisms by which attenuated viruses infect normal cells.
• To assess the significance of this off-target infection for the efficacy of oncolytic virotherapy.

Main Methods:

• Literature review focusing on studies of oncolytic virus infection in non-tumor cells.
• Emphasis on infection within the tumor microenvironment and secondary lymphoid tissues.
• Analysis of mechanisms driving viral entry into normal cells.

Main Results:

• Oncolytic viruses demonstrate tropism for various non-tumor cell types, including those within the tumor microenvironment and immune cells.
• Mechanisms for normal cell infection involve viral properties and host cell interactions, often exploiting pathways similar to tumor cell entry.
• The impact of infecting immune cells and stromal cells in the tumor microenvironment on therapeutic outcomes is complex and warrants further investigation.

Conclusions:

• Understanding the infection of normal cells by oncolytic viruses is crucial for optimizing cancer virotherapy strategies.
• Further research is needed to elucidate the precise role of non-target cell infection in modulating anti-tumor immunity and overall treatment efficacy.
• Targeting or leveraging these interactions may enhance the therapeutic potential of oncolytic viruses.